Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, CAR-T, CD19 Feb 17 | 2022BMS Receives Priority Review for Breyanzi in 2L LBCL; Breyanzi's PDUFA Date Set for June 24, 2022Access Free Blast
Free
Posted in: Autologous, CAR-T Feb 16 | 2022Legend’s CD4 CAR-T Trial in TCL is Placed on Clinical Hold by the FDAAccess Free Blast
Free
Posted in: Autologous, CAR-T Feb 14 | 20222seventy Appoints Steven Bernstein as Their New CMO; Susan Abu-Absi Appointed as 2seventy's Chief Technology and Manufacturing OfficerAccess Free Blast
Free
Posted in: Autologous, BCMA Feb 11 | 2022Legend Achieves Two Major Milestone Payments for CarvyktiAccess Free Blast
Free
Posted in: Allogeneic Feb 11 | 2022Cellectis Appoints Bing Wang as Chief Financial OfficerAccess Free Blast
Free
Posted in: Autologous, TCR Feb 09 | 2022Lete-cel’s Readout Anticipated For 2023; New GSK Expected to Launch by Mid-2022; GSK’s Q4 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 04 | 2022Breyanzi’s Sales Increase While Abecma’s Remain Flat; How Will BMS Meet CAR-T Manufacturing Demand? Breyanzi On Track for EU Approval in 2L LBCL; BMS’s Q4 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19, NVS Feb 02 | 2022Kymriah Sales Continue to Decline; Could an Approval in FL Offset Kymriah’s Revenue Loss in DLBCL? Novartis’s Q4 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Feb 02 | 2022Yescarta’s Sales Grow; Gilead Prepares for Increased Manufacturing Demands; Tecartus’s EU Approval in R/R Adult ALL Faces Delays; Gilead’s Q4 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jan 31 | 2022FDA Approves an Updated Label for Yescarta to Include Prophylactic Corticosteroids UseAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jan 28 | 2022CHMP Adopts Positive Opinion for BMS’s Breyanzi in ≥3L R/R DLBCLAccess Free Blast
Free
Posted in: Autologous, TCR Jan 26 | 2022Adaptimmune Appoints Cintia Piccina as Chief Commercial OfficerAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Jan 25 | 2022Carvykti’s FDA Approval Anticipated Around February 28, 2022; JNJ Q4 2021 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Jan 24 | 2022Could Breyanzi Receive a Positive CHMP Opinion This Week? Tecartus Continues to Experience Delays; January’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Jan 20 | 2022Abecma Approved in Japan; Can BMS Meet the Increased Manufacturing Demand? Novartis and Pack Health Explore Digital Coaching to Improve Quality of Life Outcomes Following CAR-T TreatmentAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, TCR Jan 13 | 2022JPM 2022 Day 3 & 4: Precision and TCR2 TxAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jan 12 | 2022Gracell to Open an R&D Facility in the US; JPM 2022 Days 2 & 3: Legend, Allogene, and AutolusAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jan 11 | 2022Mark Gergen Appointed as Poseida’s New CEO; Poseida and 2seventy Provide Business Updates for 2022; Allogene’s Collaboration with Antion Bio for miCAR Technology; JPM 2022 Day 2 Part 1: GSK and SpringWorksAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jan 10 | 2022Allogene's FDA Clinical Hold Lifted; JPM 2022 Day 1: BMS, Novartis, JNJ, and GileadAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.